# NCT03984448 (NCT03984448)

> Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03984448
- Phase: PHASE2, PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: National Cancer Institute (NCI)
- Conditions: Diffuse Large B-Cell Lymphoma; Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; Double-Expressor Lymphoma; EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements; High Grade B-Cell Lymphoma, Not Otherwise Specified; Neoplastic Cells With Double Expression of MYC and BCL2 Proteins Present; Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
- Interventions: Biospecimen Collection; Bone Marrow Biopsy; Computed Tomography; Cyclophosphamide; Doxorubicin Hydrochloride; Etoposide; Lumbar Puncture; Positron Emission Tomography; Prednisone; Rituximab; Venetoclax; Vincristine Sulfate
- Enrollment: 363
- Primary outcome: Progression-free survival (PFS) (phase II)
- Primary outcome: PFS (phase III)

## Indexed commentary on NCT03984448 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 4

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct03984448